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Abstract
Background: During the 2013–2016 West Africa Ebola virus disease (EVD) epidemic, some EVD patients, mostly
health care workers, were evacuated to Europe and the USA.
Case presentation: In May 2015, a 37-year old male nurse contracted Ebola virus disease in Sierra Leone. After
Ebola virus detection in plasma, he was medically-evacuated to Italy. At admission, rhabdomyolysis was clinically
and laboratory-diagnosed and was treated with aggressive hydration, oral favipiravir and intravenous investigational
monoclonal antibodies against Ebola virus. The recovery clinical phase was complicated by a febrile thrombocytopenic
syndrome with pericardial effusion treated with corticosteroids for 10 days and indomethacin for 2 months. No
evidence of recurrence is reported.
Conclusions: A febrile thrombocytopenic syndrome with pericardial effusion during the recovery phase of EVD
appears to be uncommon. Clinical improvement with corticosteroid treatment suggests that an immune-mediated
mechanism contributed to the pericardial effusion.
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Background
The 2013–6 West Africa Ebola virus disease (EVD)
epidemic resulted in 28,616 confirmed, probable and
suspected cases reported in Guinea, Liberia and Sierra
Leone, with 11,310 deaths [1]. A small number of EVD
cases were medically-evacuated or imported to Europe
and the U.S., with limited secondary transmission in
Spain and USA, in health care workers [2]. Pericardial
involvement has rarely been reported in EVD patients
[3–5]. Here we describe a case of acute rhabdomyolysis
with delayed pericardial effusion in a nurse with EVD.
Case presentation
In May 2015, a 37-year old male nurse who had been
working in Sierra Leone was admitted to the Spallanzani
Hospital, Rome, Italy for EVD clinical management.
Medical, family and psychosocial history was non-con-
tributory. Findings at admission, 3 days after symptom on-
set, included fever (39.0 °C), myalgia, conjunctivitis,
diarrhoea, rhabdomyolysis [elevated serum creatine kinase
(CK) level (785 IU/L, normal range 22–269)] with normal
renal function, and Ebola virus (EBOV) load in plasma
was 5 × 107 copies/ml.
Oral favipiravir (Toyama Chemical Co, Japan) was
administered (6-g loading dose and 1200 mg twice daily
for 10 days) [6, 7]. Two doses of investigational mono-
clonal antibodies against EBOV (MIL77, Mabworks
Beijing China) were given (50 mg/kg IV) 3 days apart.
Empiric antibiotic treatment with intravenous ceftriax-
one (2 g daily) and oral levofloxacin (750 mg daily), and
intravenous crystalloid solution, were administered daily
with progressive clinical improvement. CK level peaked
on illness day 5 (4400 IU/ml) and declined to normal on
illness day 10 (Fig. 1a). Renal function remained normal.
The plasma EBOV load was undetectable on day 11
(Fig. 1a).
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On illness day 19, a febrile syndrome with diffuse adeno-
pathy, confluent skin rash and marked thrombocytopenia
(18,000/mm3) occurred (Fig. 1b-d). ECG showed diffuse
nonspecific abnormalities in repolarisation, and an
echocardiogram showed a mild circumferential pericardial
effusion (largest echo-free space in tele-diastole <10 mm)
(Fig. 1e-f). Chest pain and pericardial rub were absent.
High-dose corticosteroid therapy was initiated with imme-
diate clinical improvement; methylprednisolone, 1 g IV
daily for 2 days, reduced to 500 mg on day 21 and 250 mg
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Fig. 1 Ebola plasma viral load, creatine kinase levels, platelet count, timing of drug administration and of occurrence of the thrombocytopenic
febrile syndrome (panel a); Skin lesions on the face and on the left thigh, and neck adenopathy (panels b-d); Echocardiographic evidence of
MILD circumferential pericardial effusion at the time of the thrombocytopenic febrile syndrome and ECG showing ECG showed diffuse
nonspecific abnormalities (panels e and f). Legend of panel A: The Y-axis indicates Ebola viral load (copies/ml) and platelet count (platelet/mm3).
The Z-axis indicates creatine kinase levels (International Units/Liter). CK creatine kinase
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on day 22, and then switched to oral prednisone on day
23, with normalization of platelet count. Serum tested
positive for rheumatoid factor, Waaler Rose, and circulat-
ing immune complexes. At discharge on illness day 29, a
minimal pericardial effusion was present. Corticosteroid
treatment was stopped and oral indomethacin 25 mg
twice daily was prescribed. Echocardiographic examin-
ation performed 60 days after discharge showed complete
resolution of the pericardial effusion and indomethacin
therapy was stopped. There was no evidence of pericardial
effusion at 18 month follow-up visit.
Discussion and conclusions
A febrile thrombocytopenic syndrome with pericardial
effusion during the recovery phase of EVD appears to
be uncommon. Pericarditis was suggested as a cause of
retrosternal pain in some patients and pericardial effusion
was confirmed in one fatal EVD case during the 1995
Kikwit outbreak [3]. Pericardial effusion was reported
in a critically ill EVD patient in Germany [4], and in
two EVD patients in Guinea in 2014 [5].
Immune activation has been described in a small
number of EVD patients [8]. In this case, EBOV infection
may have triggered inflammation resulting in rhabdo-
myolysis, and after viremia resolved, prolonged immune
activation may have caused pericardial tissue injury [9]. A
serum-sickness disease induced by the monoclonal anti-
body against EBOV that was administered is another
possible explanation [8]. Clinical improvement with
corticosteroid treatment suggests that an immune-
mediated mechanism likely contributed to the develop-
ment of the pericardial effusion.
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